Troponins and natriuretic peptides to detect cardiotoxicity: useful biomarkers or paradise lost?

Valentina Bracun; Rudolf A. de Boer

doi:10.1002/ejhf.1676

Troponins and natriuretic peptides to detect cardiotoxicity: useful biomarkers or paradise lost?

Valentina Bracun, Rudolf A. de Boer^*

^*Corresponding author for this work

Research output: Contribution to journal › Editorial › Academic › peer-review

2 Citations (Scopus)

Original language	English
Pages (from-to)	362-365
Number of pages	4
Journal	European Journal of Heart Failure
Volume	22
Issue number	2
DOIs	https://doi.org/10.1002/ejhf.1676
Publication status	Published - 1 Feb 2020
Externally published	Yes

Bibliographical note

Funding Information:
This work is supported by the European Research Council (ERC CoG 818715, SECRETE‐HF).

Funding Information:
This work is supported by the European Research Council (ERC CoG 818715, SECRETE-HF). Conflict of interest: The UMCG, which employs Dr de Boer, has received research grants and/or fees from AstraZeneca, Abbott, Bristol-Myers Squibb, Novartis, NovoNordisk, and Roche. R.A.d.B. received personal fees from Abbott, AstraZeneca, MandalMed Inc, Novartis, and Roche. V.B. has nothing to disclose.

Access to Document

10.1002/ejhf.1676

Cite this

@article{e91c1deef0c749efaab99499737706d5,

title = "Troponins and natriuretic peptides to detect cardiotoxicity: useful biomarkers or paradise lost?",

author = "Valentina Bracun and {de Boer}, {Rudolf A.}",

note = "Funding Information: This work is supported by the European Research Council (ERC CoG 818715, SECRETE‐HF). Funding Information: This work is supported by the European Research Council (ERC CoG 818715, SECRETE-HF). Conflict of interest: The UMCG, which employs Dr de Boer, has received research grants and/or fees from AstraZeneca, Abbott, Bristol-Myers Squibb, Novartis, NovoNordisk, and Roche. R.A.d.B. received personal fees from Abbott, AstraZeneca, MandalMed Inc, Novartis, and Roche. V.B. has nothing to disclose.",

year = "2020",

month = feb,

day = "1",

doi = "10.1002/ejhf.1676",

language = "English",

volume = "22",

pages = "362--365",

journal = "European Journal of Heart Failure",

issn = "1388-9842",

publisher = "John Wiley & Sons Ltd.",

number = "2",

}

TY - JOUR

T1 - Troponins and natriuretic peptides to detect cardiotoxicity

T2 - useful biomarkers or paradise lost?

AU - Bracun, Valentina

AU - de Boer, Rudolf A.

N1 - Funding Information: This work is supported by the European Research Council (ERC CoG 818715, SECRETE‐HF). Funding Information: This work is supported by the European Research Council (ERC CoG 818715, SECRETE-HF). Conflict of interest: The UMCG, which employs Dr de Boer, has received research grants and/or fees from AstraZeneca, Abbott, Bristol-Myers Squibb, Novartis, NovoNordisk, and Roche. R.A.d.B. received personal fees from Abbott, AstraZeneca, MandalMed Inc, Novartis, and Roche. V.B. has nothing to disclose.

PY - 2020/2/1

Y1 - 2020/2/1

UR - http://www.scopus.com/inward/record.url?scp=85078039643&partnerID=8YFLogxK

U2 - 10.1002/ejhf.1676

DO - 10.1002/ejhf.1676

M3 - Editorial

C2 - 31944511

AN - SCOPUS:85078039643

SN - 1388-9842

VL - 22

SP - 362

EP - 365

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

IS - 2

ER -

Troponins and natriuretic peptides to detect cardiotoxicity: useful biomarkers or paradise lost?

Bibliographical note

Access to Document

Other files and links

Cite this